GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Orient Europharma Co 4120.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

42.05

-0.59%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 4.60bn

FY2016FY2025

Net income

−TWD 567.4m

FY2016FY2025

Free cash flow

−TWD 480.9m

FY2016FY2025

Shareholders' equity

TWD 6.29bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 4.60bnTWD 4.39bnTWD 4.59bnTWD 4.73bnTWD 4.77bnTWD 5.38bnTWD 6.09bnTWD 5.51bnTWD 5.23bnTWD 5.23bn
Gross profitTWD 2.24bnTWD 2.07bnTWD 2.15bnTWD 2.03bnTWD 2.15bnTWD 2.42bnTWD 2.81bnTWD 2.58bnTWD 2.47bnTWD 2.41bn
Research and developmentTWD 558.4mTWD 242.2mTWD 206.6mTWD 259.8mTWD 331.1mTWD 366.6mTWD 394.6mTWD 389.5mTWD 378.8mTWD 363.4m
Operating income−TWD 298.8mTWD 13.3mTWD 72.1m−TWD 279.6mTWD 111.0mTWD 117.4mTWD 336.4mTWD 357.2mTWD 435.4mTWD 450.9m
Net income−TWD 567.4m−TWD 283.9mTWD 143.9m−TWD 310.8mTWD 120.2mTWD 199.3mTWD 247.7mTWD 246.7mTWD 458.7mTWD 469.6m
Diluted earnings per share-6.54-3.271.66-3.581.392.302.862.845.295.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 12.21bnTWD 11.57bnTWD 10.81bnTWD 10.43bnTWD 9.40bnTWD 8.16bnTWD 7.87bnTWD 7.24bnTWD 6.65bnTWD 6.49bn
Total liabilitiesTWD 4.85bnTWD 5.75bnTWD 6.65bnTWD 6.99bnTWD 5.95bnTWD 4.25bnTWD 4.06bnTWD 3.10bnTWD 2.56bnTWD 2.57bn
DebtTWD 925.0mTWD 4.23bnTWD 4.84bnTWD 5.02bnTWD 4.22bnTWD 2.40bnTWD 2.17bnTWD 1.43bnTWD 953.4mTWD 1.17bn
Shareholders' equityTWD 6.29bnTWD 5.16bnTWD 3.51bnTWD 2.93bnTWD 2.94bnTWD 3.21bnTWD 3.19bnTWD 3.28bnTWD 3.27bnTWD 3.14bn
Shares outstanding87m87m87m87m87m87m87m87m87m87m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−TWD 292.2m−TWD 121.1mTWD 64.7m−TWD 218.8mTWD 77.6mTWD 608.5mTWD 227.4mTWD 231.3mTWD 601.1mTWD 111.2m
Capital spending−TWD 188.6m−TWD 100.2m−TWD 100.7m−TWD 639.2m−TWD 1.56bn−TWD 232.8m−TWD 125.0m−TWD 201.6m−TWD 367.7m−TWD 224.8m
Free cash flow−TWD 480.9m−TWD 221.3m−TWD 36.0m−TWD 857.9m−TWD 1.49bnTWD 375.8mTWD 102.4mTWD 29.7mTWD 233.4m−TWD 113.6m
Dividends paid−TWD 101.0m−TWD 101.0m−TWD 15.6m−TWD 73.7m−TWD 130.1m−TWD 156.1m−TWD 156.1m−TWD 216.9m−TWD 156.1m−TWD 170.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 1.19bnTWD 1.15bnTWD 1.20bnTWD 1.12bnTWD 1.13bnTWD 1.16bnTWD 1.13bnTWD 1.07bn
Gross profitTWD 558.5mTWD 598.5mTWD 558.9mTWD 553.3mTWD 568.0mTWD 557.1mTWD 522.2mTWD 486.6m
Operating income−TWD 62.4mTWD 35.1m−TWD 203.2m−TWD 53.1m—−TWD 73.5mTWD 9.5mTWD 65.7m
Net income−TWD 183.0m−TWD 25.0m−TWD 239.1m−TWD 128.8m−TWD 45.7m−TWD 153.7m−TWD 134.9mTWD 11.4m
Diluted earnings per share-2.11-0.29-2.76-1.49-0.53-1.77-1.560.13
Cash from operations−TWD 305.0mTWD 15.0m−TWD 155.0m−TWD 157.0mTWD 33.0m−TWD 12.0mTWD 97.0mTWD 69.0m
Capital spending−TWD 72.0m−TWD 88.0m−TWD 34.0m−TWD 47.0m−TWD 89.0m−TWD 16.0m−TWD 37.0m−TWD 21.0m
Free cash flow−TWD 377.0m−TWD 73.0m−TWD 189.0m−TWD 204.0m−TWD 56.0m−TWD 28.0mTWD 60.0mTWD 48.0m
Total assetsTWD 11.75bnTWD 11.61bnTWD 12.21bnTWD 12.43bnTWD 12.21bnTWD 11.82bnTWD 11.57bnTWD 12.33bn
DebtTWD 925.2mTWD 902.8mTWD 925.0mTWD 861.6mTWD 1.20bnTWD 1.26bnTWD 1.34bnTWD 1.40bn
Shareholders' equityTWD 5.23bnTWD 5.67bnTWD 6.29bnTWD 6.86bnTWD 6.20bnTWD 5.51bnTWD 5.16bnTWD 5.22bn

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin48.7%47.1%46.8%43.0%45.1%45.0%—
Operating margin-4.3%-0.5%7.9%-3.2%-2.0%2.2%—
Net margin-12.3%-6.5%3.1%-6.6%2.5%3.7%—
Return on equity-9.0%-5.5%4.1%-10.6%4.1%6.2%—
Return on assets-4.6%-2.5%1.3%-3.0%1.3%2.4%—
Free cash flow yield—-0.5%4.2%10.7%41.6%21.3%8.9%
Revenue growth4.6%-4.4%-2.9%-0.8%-11.5%-11.6%—
Earnings growth99.8%-297.3%-146.3%-358.6%-39.7%-19.5%—
Current ratio1.47x1.20x1.14x1.10x1.21x1.78x—
Debt to equity0.15x0.26x0.51x0.68x0.57x0.24x—
Equity ratio51.5%44.6%32.5%28.1%31.3%39.3%—
Interest coverage-2.69x-0.21x3.42x-2.15x-2.52x3.88x—
R&D as a share of sales12.2%5.5%4.5%5.5%6.9%6.8%—
Buybacks as a share of market value—0.0%0.0%0.0%0.0%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.0%-3.1%-0.7%
Operating income2.2%——
Net income22.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin47.9%46.3%45.9%46.0%
Operating margin-3.2%-2.7%-0.9%2.8%
Net margin-9.5%-5.6%-2.5%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-6.8-14.723.4-10.126.220.919.518.315.011.5
Price to sales0.80.90.70.70.70.80.80.81.31.0

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 7 Jul 2025.

FY2025FY2024FY2022
Paid in the year1.001.000.85
  • 1160-for-1000 split · 28 Jul 2010
  • 1.14207-for-1 split · 13 Aug 2009
  • 1.0999-for-1 split · 29 Jul 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.